Skip to main content
SpringerLink
Log in

Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

A better understanding of the relationship between glioblastomas molecular subtypes and radio-chemotherapy is needed for the development of individualized strategies. In this study, we aimed to assess whether non-homologous end-joining (NHEJ) protein expression is associated and could predict responses to treatment of mesenchymal (MES) and proneural (PN) subtypes. Tumors from 122 patients with a glioblastoma treated at the University Hospital of Poitiers between 2002–2013 by an association of radiotherapy and temozolomide were collected. Among these tumors, 80 were suitable for in situ analysis and were included in TissueMicroArray. The expression of DNA-PKcs, Ku70, Ku80 and CD44, Olig2 (respectively surrogate markers of MES and PN subtypes) were evaluated by immunohistochemistry. The median survival of patients with high and low CD44 expression was 11.9 months (95% CI 7.7–14) and 19.1 months (95% CI 15.2–22.4) respectively (p = 0.008). Median survival of patients with high and low DNA-PKcs levels was 20.0 months (95% CI 15.2–25.3) and 12.9 months (95% CI 9.9–19.5) respectively (p = 0.036). High levels of Olig2, Ku70 and Ku80 tended to be associated with better overall survival but no significant differences were found. Overall survival of class I patients (CD44+ and DNA-PKcs+) was longer than class II (CD44+ and DNA-PKcs− or CD44− and DNA-PKcs+) and class III (CD44− and DNA-PKcs−), (p = 0.005 and 0.003 respectively). High levels of CD44 and DNA-PK are associated with a better survival and better response to radiotherapy and temozolomide and could establish prognosis classes by predicting survival and response to therapy for GBMs patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  CAS  Google Scholar 

  2. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173

    Article  CAS  Google Scholar 

  3. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17(1):98

    Article  CAS  Google Scholar 

  4. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F et al (2013) Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24(3):331–346

    Article  CAS  Google Scholar 

  5. Pries R, Witrkopf N, Trenkle T, Nitsch SM, Wollenberg B (2008) Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. Vivo Athens Greece 22(1):89–92

    Google Scholar 

  6. Wang W, Dong L-P, Zhang N, Zhao C-H (2014) Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis. Int J Clin Exp Med 7(12):5059–5066

    PubMed  PubMed Central  Google Scholar 

  7. Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH et al (2009) Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 59(4):241–246

    Article  CAS  Google Scholar 

  8. Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV et al (2003) CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res Off J Am Assoc Cancer Res 9(14):5318–5324

    Google Scholar 

  9. Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY et al (2001) OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 358(9278):298–300

    Article  CAS  Google Scholar 

  10. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760

    Article  CAS  Google Scholar 

  11. Bouchaert P, Guerif S, Debiais C, Irani J, Fromont G (2012) DNA-PKcs expression predicts response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1179–1185

    Article  CAS  Google Scholar 

  12. Lee S-W, Cho K-J, Park J-H, Kim SY, Nam SY, Lee B-J et al (2005) Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 62(5):1451–1457

    Article  CAS  Google Scholar 

  13. Kase M, Vardja M, Lipping A, Asser T, Jaal J (2011) Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme. Radiother Oncol J Eur Soc Ther Radiol Oncol 101(1):127–131

    Article  CAS  Google Scholar 

  14. Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncol 6(3):227–235

    Article  Google Scholar 

  15. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003

    Article  CAS  Google Scholar 

  16. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773.

    Article  CAS  Google Scholar 

  17. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718

    Article  Google Scholar 

  18. Wei K-C, Huang C-Y, Chen P-Y, Feng L-Y, Wu T-WE, Chen S-M et al (2010) Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res 30(1):253–259

    CAS  PubMed  Google Scholar 

  19. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL et al (2015) Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol Off J Am Soc Clin Oncol 33(25):2735–2744

    Article  CAS  Google Scholar 

  20. Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A et al (2014) A mesenchymal glioma stem cell profile is related to clinical outcome. Oncogenesis 3(3):e91

    Article  CAS  Google Scholar 

  21. Welsh JW, Ellsworth RK, Kumar R, Fjerstad K, Martinez J, Nagel RB et al (2009) Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 74(4):1251–1255

    Article  CAS  Google Scholar 

  22. Hine CM, Seluanov A, Gorbunova V (2008) Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA 105(52):20810–20815

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Funding

Funding for this work was provided by the Ligue contre le Cancer de la Vienne, des Deux-Sèvres, de la Charente Maritime, and the “Sport et Collection” foundations

Author information

Authors and Affiliations

  1. CHU de Poitiers Department of Cancer Biology, Université de Poitiers, Poitiers, France

    Baptiste Pinel & Lucie Karayan-Tapon

  2. CHU de Poitiers Department of Radiotherapy, Université de Poitiers, Poitiers, France

    Baptiste Pinel & Antoine Berger

  3. CHU de Poitiers Department of Pathology, Université de Poitiers, Poitiers, France

    Mathilde Duchesne, Julie Godet & Serge Milin

  4. CHU de Poitiers Department of Neurosurgery, Université de Poitiers, Poitiers, France

    Michel Wager

  5. INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, Cellular Therapies in Brain Diseases Group, University of Poitiers, Poitiers, France

    Michel Wager & Lucie Karayan-Tapon

  6. Department of Cancer Biology, University Hospital of Poitiers, 86021, Poitiers, France

    Lucie Karayan-Tapon

Authors
  1. Baptiste Pinel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathilde Duchesne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie Godet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Serge Milin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Antoine Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michel Wager
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lucie Karayan-Tapon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucie Karayan-Tapon.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest related to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPTX 339 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pinel, B., Duchesne, M., Godet, J. et al. Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide. J Neurooncol 132, 287–294 (2017). https://doi.org/10.1007/s11060-016-2367-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-016-2367-7

Keywords

Search

Navigation